Moreover, beta-blocker therapy should be preferred in hypertensive OSA patients in the presence of CAD, arrhythmia, or heart failure, whereas SGLT-2 inhibitors and renal denervation therapy may be considered as an option in patients refractory to standard therapy. Here, SLC5A2 is linked to obstructive sleep apnea syndrome.